Targeting the essentialome of radiotherapy-resistant cancer

Informazioni relative al progetto

TETHER

ID dell’accordo di sovvenzione: 883877

DOI 10.3030/883877

Data della firma CE 28 Maggio 2020

Data di avvio 1 Ottobre 2021

Data di completamento 30 Settembre 2026

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale € 2 499 875,00

Contributo UE € 2 499 875,00

Coordinato da

UNIVERSITAET BERN
Switzerland

Pubblicazioni

Peer reviewed articles (13)

Meiotic Genes and DNA Double Strand Break Repair in Cancer

Autori: Lea Lingg, Sven Rottenberg, Paola Francica
Pubblicato in: Frontiers in Genetics, 2022, ISSN 1664-8021
Editore: Frontiers Media
DOI: 10.3389/fgene.2022.831620

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

Autori: Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma SR, de Bruijn R, de Ruiter JR, van den Broek B, Duarte AA, Sol W, van der Heijden I, Andronikou C, Kaiponen TS, Bakker L, Lieftink C, Morris B, Beijersbergen RL, van de Ven M, Jimenez CR, Wessels LFA, Rottenberg S, Jonkers J
Pubblicato in: Cell Reports, 2023, ISSN 2211-1247
Editore: Cell Press
DOI: 10.1016/j.celrep.2023.112538

LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus

Autori: Gradauskaite, Vaiva; Inglebert, Marine; Doench, John; Scherer, Melanie; Dettwiler, Martina; Wyss, Marianne; Shrestha, Neeta; Rottenberg, Sven; Plattet, Philippe
Pubblicato in: mBio, 2023, ISSN 2150-7511
Editore: American Society for Microbiology
DOI: 10.1128/mbio.03114-22

Persisting cancer cells are different from bacterial persisters

Autori: Decollogny, Morgane; Rottenberg, Sven
Pubblicato in: Trends in Cancer, Numero 10(5):393-406, 2024, ISSN 2405-8025
Editore: CellPress
DOI: 10.1016/j.trecan.2024.02.002

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

Autori: Andronikou, Christina; Burdova, Kamila; Dibitetto, Diego; Lieftink, Cor; Malzer, Elke; Kuiken, Hendrik J; Gogola, Ewa; Ray Chaudhuri, Arnab; Beijersbergen, Roderick L; Hanzlikova, Hana; Jonkers, Jos; Rottenberg, Sven
Pubblicato in: The EMBO Journal, Numero 43(6):1015-1042, 2024, ISSN 0261-4189
Editore: Nature Publishing Group
DOI: 10.1038/s44318-024-00043-2

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

Autori: Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ
Pubblicato in: Cell Reports, 2023, ISSN 2211-1247
Editore: Cell Press
DOI: 10.1016/j.celrep.2023.112484

Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

Autori: Widmer CA, Klebic I, Domanitskaya N, Decollogny M, Howald D, Siffert M, Essers P, Nowicka Z, Stokar-Regenscheit N, van de Ven M, de Korte-Grimmerink R, Galván JA, Pritchard CEJ, Huijbers IJ, Fendler W, Vens C, Rottenberg S
Pubblicato in: Cancer Research Communications, 2022, ISSN 2767-9764
Editore: American Association for Cancer Research
DOI: 10.1158/2767-9764.crc-22-0208

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

Autori: Diego Dibitetto; Martin Liptay; Francesca Vivalda; Ewa Gogola; Hulya Dogan; Martín G. Fernández; Alexandra Duarte; Jonas A. Schmid; Stephen T. Durant; Josep V. Forment; Ismar Klebic; Myriam Siffert; Roebi de Bruijn; Arne N. Kousholt; Nicole A. Marti; Martina Dettwiler; Claus S. Sørensen; Massimo Lopes; Alessandro A. Sartori; Jos Jonkers; Sven Rottenberg
Pubblicato in: Nature Communications, Numero 4430 (2024), 2024, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1101/2023.05.22.541781

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

Autori: Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group
Pubblicato in: Lancet Oncology, Numero 25(2):e73-e83, 2024, ISSN 1470-2045
Editore: The Lancet Publishing Group
DOI: 10.1016/s1470-2045(23)00534-x

DNA-PKcs promotes fork reversal and chemoresistance

Autori: Dibitetto D, Marshall S, Sanchi A, Liptay M, Badar J, Lopes M, Rottenberg S, Smolka MB
Pubblicato in: Molecular Cell, 2022, ISSN 1097-2765
Editore: Cell Press
DOI: 10.1016/j.molcel.2022.08.028

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Autori: Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink
Pubblicato in: Nature, 2022, ISSN 0028-0836
Editore: Nature Publishing Group
DOI: 10.1038/s41586-022-05066-5

DNA repair, gap suppression, or fork protection: BRCA2 needs a break!

Autori: Diego Dibitetto, Sven Rottenberg
Pubblicato in: Molecular Cell, Numero 84(3):409-410, 2024, ISSN 1097-2765
Editore: Cell Press
DOI: 10.1016/j.molcel.2023.12.026

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids

Autori: Paes Dias M, Rottenberg S, Jonkers J.
Pubblicato in: Star Protocols, 2022, ISSN 2666-1667
Editore: Elsevier
DOI: 10.1016/j.xpro.2022.101132